Skip to content
Stay curious ↗

Follow your curiosity.

Try “brain”, “genomics”, or another subject you follow.

Today/Drug Development
Drug Development · The big question

Early Trial Shows Promise for Lassa Fever Drug

Favipiravir for Lassa fever: an open-label, randomized controlled phase 2 trial

Nature Medicine1 min readAI-assisted summary
Editorial illustration for Favipiravir for Lassa fever: an open-label, randomized controlled phase 2 trial
Editorial illustration

Summary

Researchers in Nigeria have recently completed an early-stage clinical study looking for alternative ways to treat Lassa fever. The disease is currently managed with a medication called ribavirin. In this new study, scientists wanted to see if a different antiviral drug named favipiravir could serve as a viable substitute for patients with mild-to-moderate symptoms.

The research team conducted a Phase 2 open-label trial. In an open-label study, both the medical staff and the patients know exactly which medication is being administered. As a Phase 2 trial, the primary goal was to observe if the medication is safe for patients to take. The results were encouraging, showing that favipiravir was safe and well-tolerated by the individuals who received it. This success suggests that researchers can now move forward with optimizing the drug for broader use.

However, it is important to view these findings as an early step in the scientific process. The researchers noted that because this was an early-stage study, the abstract does not disclose the total number of participants or the specific, quantitative measurements of how effectively the drug fights the virus. More rigorous research will be needed to fully understand how well favipiravir performs compared to existing treatments.

Why it matters.

Developing a safe and well-tolerated alternative to standard treatments is a vital step forward for patients facing Lassa fever. Currently, the primary treatment is ribavirin, and proving that favipiravir is safe opens the door for scientists to optimize it as a secondary option. Having multiple therapies available is critical in medicine, as it provides doctors with backup plans if a primary treatment is unavailable or unsuitable for a specific patient.

Looking ahead, these results lay the necessary groundwork for more advanced medical research. While the medical community still needs to see large-scale data on how effectively the drug eliminates the virus, establishing its safety is a major milestone. If favipiravir continues to succeed in future, larger clinical trials, it could eventually expand the available treatments for Lassa fever and improve overall patient care in affected regions.

From the source

The story in numbers.

Clinical trial phase
2
Publication year
2026
Keep the context

Follow the evidence.

This AI-assisted summary is a starting point. Read the original reporting for its methods, scope, and limitations.

Your next discovery.

Keep exploring ↗
Drug Development

A $122M boost for a fast, inside-the-body approach to cell therapy

Create Medicines recently secured $122 million to advance a new class of treatments for cancer and autoimmune diseases. They specialize in CAR-T cell therapy, a treatment that engineers the immune system to fight disease. But instead of the traditional method of removing cells from a patient to alter them in a lab, Create Medicines is developing therapies that work entirely inside the body, a process known as "in vivo" treatment. To achieve this, the therapy uses tiny fat bubbles called lipid nanoparticles to deliver messenger RNA, or mRNA, into the patient. Think of mRNA as a set of biological instructions. Once delivered, these instructions directly teach the patient's existing immune cells, including T cells, natural killer cells, and myeloid cells, to reprogram themselves into disease fighters. The startup has already dosed more than 50 patients, giving it the largest clinical dataset in the in vivo field. They recently began an early-stage clinical trial for an experimental therapy designed to attack solid tumors that carry a specific protein called HER2. Alongside this cancer research, the company is testing other treatments that target proteins called CD19 and BCMA to help patients with autoimmune conditions.

BioPharma Dive1 min read
Drug Development

Supreme Court Protects Access to Common Abortion Pill

The United States Supreme Court has decided to preserve access to mifepristone, a medication used in the most common method of abortion. By rejecting recent restrictions proposed by lower courts, the Supreme Court has ensured that patients can still obtain this widely used drug while an ongoing lawsuit continues to make its way through the legal system. Under this current legal order, patients do not need an in-person visit with a doctor to get the medication. Instead, they are permitted to continue receiving mifepristone directly from pharmacies or through the mail. This ruling maintains the existing distribution methods, meaning that access is expected to remain uninterrupted at least into the following year as further legal proceedings unfold.

STAT News1 min read
Drug Development

Living Implants: Engineered Bacteria Trapped in Gel Fight Infections

What if a medical implant could sense an infection and fight it off automatically? Researchers have created exactly that with a new technology called an "implantable living material." To build it, scientists used a specialized, water-based gel known as a polyvinyl alcohol hydrogel. This material acts as a tiny, flexible fortress. It is uniquely stiff and tough, designed to hold genetically engineered bacteria safely inside for up to six months without them escaping into the surrounding tissue. Inside this protective gel, the researchers trapped a modified version of E. coli bacteria to act as molecular guards. These engineered microbes are programmed to detect chemical signals given off by Pseudomonas aeruginosa, a dangerous pathogen that frequently causes infections around artificial joints. When the trapped bacteria sense the invader, they trigger a targeted self-destruct mechanism. This intentional cellular explosion releases a powerful antibacterial protein that easily passes through the microscopic pores of the gel to kill the infection outside. The research team tested this system in mice with artificial joint infections. Over a three-day treatment period, the living implant significantly reduced the amount of infectious bacteria compared to non-therapeutic controls. By keeping the helpful microbes physically contained while allowing their medicine to flow out, the researchers have found a clever way to turn living cells into localized drug factories.

GEN2 min read

A little science goes a long way.

Clear, thoughtful biotech briefings. In your inbox three times a week.

Stay curious. Subscribe free ↗
Early Trial Shows Promise for Lassa Fever Drug — Daily Strand